The Relationship Between Cardiac Output and Microvascular Visceral Blood Flow

January 26, 2015 updated by: University of Nottingham

Investigation of the Relationship Between Oesophageal Doppler Assessed Increases in Cardiac Output and Microvascular Visceral Blood Flow in Healthy Volunteers

Although major surgery is often required to treat abdominal problems, there is a significant risk of death or complication following these operations. By using ultrasound the amount and timing of fluid patients receive during operations can be optimised and the risk of surgery reduced. However, little is known about the exact changes in blood flow in the small vessels of the body in response to fluid. A greater understanding of this may allow for more appropriate care of patients undergoing this type of surgery in the future.

In this study of healthy volunteers we will attempt to better understand how fluid administration guided by ultrasound effects blood flow in large and small vessels, by using two different techniques of ultrasound imaging. A narrow bore (approximately 4-5mm diameter) ultrasound probe will be passed through the nostril and mouth to rest within the oesophagus allowing measurement of blood flow in the main artery, while a second probe will be rested on the volunteer's abdomen and used to record changes in blood flow in small liver blood vessels. Comparison of these two techniques during the administration of fluid will allow us to better understand the relationship between large and small vessel blood flow.

Because different types of fluid may behave in different ways, we will test the effect of two types of fluid commonly used in clinical practice; 'normal' saline solution and gelofusine.

Study Overview

Detailed Description

Optimizing intravascular volume and cardiac output are essential to ensure adequate organ perfusion in patients who are undergoing major surgery. To enable this cardiac output is frequently monitored during operation using a variety of techniques; one such technique is trans-oesophageal Doppler ultrasound also known as oesophageal Doppler monitoring (ODM). ODM measurement of cardiac output is a less invasive technique than many currently used methods, and has recently been recommended by NICE for adoption in clinical practice.

The matching of microvascular blood flow, cardiac output and fluid administration is advantageous for visceral organs, in marrying demands for oxygen and nutrients to their delivery. However, although there is evidence to suggest that intraoperative ODM directed fluid administration can improve outcomes in the perioperative period, reducing hospital stay and complications, there is little direct evidence that optimization of cardiac output via ODM improves the microvascular blood flow to the visceral organs which are frequently compromised by major surgical interventions. A greater appreciation of the effect of ODM guided fluid replacement on the delivery of blood and hence oxygen and nutrients to these vital organs could help with the development of more refined algorithms for fluid administration in a clinical setting in the future. In our clinical physiology laboratories we regularly employ contrast-enhanced ultrasound (CEUS) using a Phillips iU22, to visualize microvascular blood flow in healthy young and elderly men following a variety of physiological challenges. This minimally invasive ultrasound based imaging technique is ideal for gaining an insight into the effect various physiological interventions have on tissue blood flow and could be readily used to chart changes in visceral microvascular flow following ODM guided fluid optimization. Transference of this investigative approach to a clinical setting has the potential to greatly improve the care of the surgical patient requiring fluid resuscitation.

Different types of intravenous fluids are used in clinical practice. These are primarily crystalloid solutions, such as 0.9% sodium chloride ('normal' saline), or colloidal suspensions, such as gelofusine. There is good experimental evidence that the colloid gelofusine produces a greater effect on cardiac output than an equivalent volume of of saline, but it is unclear if this effect is replicated in the microvasculature.

We will test the hypotheses: (1) cardiac output and stroke volume as measured by ODM are determinants of visceral microvascular blood flow (2) visceral microvascular blood flow in elderly individuals is more closely determined by stroke volume (3) gelofusine produces a greater increase in microvascular blood flow than the same volume of normal saline.

Study Type

Observational

Enrollment (Actual)

24

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Derbyshire
      • Derby, Derbyshire, United Kingdom, DE22 3DT
        • University of Nottingham, School of Medicine, Division of Medical Sciences and Graduate Entry Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

Healthy male volunteers, aged 18-80.

Description

Inclusion Criteria:

  • male
  • age 18-80 years
  • body mass index 20-30kg/m2

Exclusion Criteria:

  • BMI < 20 or > 30 kg/m2.
  • Active cardiovascular disease: uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arhythmias , right to left cardiac shunt or recent cardiac event.
  • Individuals taking beta-adrenergic blocking agents.
  • Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)..
  • Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes.
  • Active inflammatory bowel disease, or renal disease,
  • Malignancy
  • Clotting dysfunction
  • Previous oesophageal surgery
  • Individuals with a known history of oesophageal varices
  • Individuals with a known history of epistaxis
  • Family history of early (<55y) death from cardiovascular disease.
  • Known sensitivity to SonoVue
  • Known sensitivity to gelofusine

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Volunteers receiving 0.9% NaCl
Volunteers receiving 0.9% NaCl to optimise stroke volume
Volunteers administered 0.9% NaCl solution in 250ml boluses
Other Names:
  • Saline
  • Normal saline
The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
Other Names:
  • CEUS
  • Contrast enhanced ultrasound scan
  • SonoVue.
Volunteers receiving gelofusine
Volunteers receiving gelofusine to optimise stroke volume
The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
Other Names:
  • CEUS
  • Contrast enhanced ultrasound scan
  • SonoVue.
Volunteers administered gelofusine in 250ml boluses

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in microvascular visceral blood flow
Time Frame: 30 minutes
Microvascular visceral blood flow is assessed using contrast enhanced ultrasound scanning, following stroke volume optimisation.
30 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in stroke volume
Time Frame: 30 minutes
The change in stroke volume will be assessed using an Oesophageal Doppler Monitor, and will be assessed pre- and post-intravenous fluid administration.
30 minutes
Change in haematocrit
Time Frame: 60 minutes
The change in the haematocrit will be measured pre- and post-intravenous fluid administration.
60 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2013

Primary Completion (ACTUAL)

March 1, 2014

Study Completion (ACTUAL)

August 1, 2014

Study Registration Dates

First Submitted

June 16, 2014

First Submitted That Met QC Criteria

June 16, 2014

First Posted (ESTIMATE)

June 18, 2014

Study Record Updates

Last Update Posted (ESTIMATE)

January 27, 2015

Last Update Submitted That Met QC Criteria

January 26, 2015

Last Verified

January 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A12012012

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteers

Clinical Trials on Administration of 0.9% NaCl solution

Subscribe